[Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
Adjuvant chemotherapy for breast cancer patients has been derived from the results of various clinical studies and metaanalysis. Currently, an anthracycline-containing regimen is a standard chemotherapy for node-negative breast cancer patients with any risk of recurrence. Node-positive breast cancer patients employ AC followed by taxane. The concept of dose-dense therapy or adjuvant trastuzumab for HER 2-positive breast cancer patients will be introduced in the near future. We have to catch the procedures of standard treatments and treat our patients with the latest knowledge. Therefore, we can refer to any guidelines based on evidence-based medicine.
Dept. of Chemotherapy, Cancer Institute Ariake Hospital.
Nahomi
N
Tokudome
Yoshinori
Y
Ito
D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide; D015251:Epirubicin; D019317:Evidence-Based Medicine; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D017408:Guidelines as Topic; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D015201:Meta-Analysis as Topic; D008727:Methotrexate / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D002945:Cisplatin; D003520:Cyclophosphamide; D015251:Epirubicin; D005472:Fluorouracil; D008727:Methotrexate; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C080625:taxane